Clinical Trial Detail

NCT ID NCT02413827
Title A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Celldex Therapeutics
Indications

melanoma

Therapies

Nivolumab + Varlilumab

Rasdegafusp alfa

Poly ICLC

Age Groups: adult

No variant requirements are available.